Bone Biologics (BBLG) Cash from Investing Activities (2014 - 2015)
Bone Biologics (BBLG) posted quarterly Cash from Investing Activities of -$504.0 for Q1 2015, down 102.68% year-over-year from $18820.0 in Q1 2014, and up 95.77% quarter-over-quarter from -$11901.0 in Q4 2014.
Powered by 
Analysis
Bone Biologics (BBLG) Cash from Investing Activities (2014 - 2015) Analysis & Trends
Bone Biologics (BBLG) has reported Cash from Investing Activities for 2 consecutive years, with -$504.0 the latest figure, recorded in Q1 2015.
- In Q1 2015, Cash from Investing Activities fell 102.68% year-over-year to -$504.0; the TTM figure through Dec 2015 stood at -$504.0 (down 101.98% YoY), while the FY2015 annual figure was -$504.0, down 101.98% from the prior year.
- Cash from Investing Activities advanced to -$504.0 in Q1 2015 per BBLG's latest filing, from -$11901.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $18820.0 in Q1 2014 and bottomed at -$11901.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2015 | -504.00 |
| Dec 31, 2014 | -11,901.00 |
| Jun 30, 2014 | 18,557.00 |
| Mar 31, 2014 | 18,820.00 |